OpGen Announces Acquisition of Preferred Stock by David Lazar
- David Lazar invests $3 million in OpGen through Series E Preferred Stock purchase.
- Proceeds to be used to repay outstanding debts and for general corporate purposes.
- Lazar appointed to OpGen's Board of Directors and will take over as CEO.
- OpGen settles outstanding liabilities with EIB and Curetis GmbH through financing.
- Settlement agreements reached with EIB and Curetis trustee to clear debts.
- Shares of Series E Preferred Stock convertible into OpGen's common stock.
- New board members appointed to enhance corporate governance.
- Strategic options to drive shareholder value to be explored under new leadership.
- None.
Insights
The infusion of $3 million in preferred stock by David Lazar into OpGen represents a significant capital injection aimed at stabilizing the company's financial position. By addressing outstanding debts with the European Investment Bank and Curetis GmbH, OpGen is effectively restructuring its balance sheet, which could lead to improved financial ratios and potentially better credit terms in the future. This move may be viewed positively by investors as it signals a commitment to financial health and could reduce the risk of insolvency.
Furthermore, the conversion feature of the Series E Preferred Stock introduces a potential future dilution of common stock, which shareholders should monitor closely. The conversion rate of 1:24 suggests a significant increase in the number of shares outstanding if fully converted, which could impact the stock price and existing shareholders' equity.
Lastly, the appointment of David Lazar as CEO and the reshuffling of the board could lead to strategic shifts within the company. Lazar's statement about exploring strategic options to drive shareholder value might indicate potential mergers, acquisitions, or divestitures on the horizon. Stakeholders should track the strategic moves closely, as they could affect the company's direction and stock performance.
OpGen's settlement of liabilities and the subsequent leadership changes are likely to alter market perception of the company. The market typically responds favorably to reductions in debt and clear plans for future growth, which could be the case here if the new leadership team successfully communicates and implements a compelling strategic vision.
Additionally, the life sciences sector, where OpGen operates, is highly competitive and sensitive to innovation and regulatory changes. The new board's ability to navigate these challenges while capitalizing on the company's strengths will be critical for long-term success. Investors will be interested in the new CEO's approach to harnessing the company's assets, including the Curetis and Ares Genetics businesses and how these could be leveraged for growth or monetization.
The complete overhaul of OpGen's board and the appointment of a new CEO are indicative of a major governance shift. Such changes can be disruptive, but they can also bring fresh perspectives and strategies to a company. It is essential for investors to assess the track record of the incoming board members and CEO to gauge their potential impact on the company's governance and strategic direction.
Moreover, the swift resignation of the entire previous board raises questions about the circumstances leading to this transition. While not uncommon in cases of significant investment and change in control, it is important for the new leadership to maintain transparency and clear communication with shareholders to build trust and support for the new direction.
- David Lazar invests
$3 million in Preferred Stock - New OpGen Board of Directors appointed
- David Lazar will take over as CEO of OpGen
- OpGen settles outstanding liabilities with EIB
ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of
On March 25, 2024, Mr. Lazar paid
In connection with the transactions, Mr. Lazar was also appointed to the Board of Directors of OpGen, and following closing will be appointed CEO. In addition, effective as of the initial closing, each of the prior members of the Company’s board of directors resigned and Oliver Schacht, PhD, resigned as CEO. Mr. Schacht will continue to serve as Executive Vice President of Corporate Development to assist with the transition period following the transactions. In addition to the appointment of Mr. Lazar as a director, each of Messrs. Avraham Ben-Tzvi, Matthew McMurdo, and David Natan were also appointed to the board of the Company, effective as of the initial closing on March 25, 2024.
In connection with the foregoing transaction, OpGen entered into settlement agreements with each of the European Investment Bank (“EIB”) and Curetis GmbH, the Company’s subsidiary (“Curetis”), and Curetis’ trustee in insolvency, pursuant to which the Company settled outstanding liabilities amongst the parties. Pursuant to the settlement agreements and the securities purchase agreement with Mr. Lazar, following closing of securities purchase agreement the Company will pay
Mr. Lazar, the new Chairman of OpGen, issued the following statement: “I am pleased to announce my significant investment in OpGen given the meaningful opportunity I believe the Company represents and am eager to begin working with the Board of Directors and management to actively explore potential strategic options to drive shareholder value.”
Oliver Schacht, PhD, former CEO of OpGen and now Executive VP of Corporate Development commented: “We are pleased with the outcome of our strategic process. With Curetis and Ares Genetics businesses and assets being sold by the respective trustees in Germany and Austria to strategic acquirors, this financing transaction provides an opportunity for OpGen to settle its outstanding liabilities with its major creditors. We believe the transaction also offers future opportunities for OpGen stockholders to participate in possible future strategic transactions under the leadership of David Lazar and the new members of the board.
About David E. Lazar
David E. Lazar is an experienced private investor who brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions.
About OpGen, Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, both of which are subject to insolvency proceedings under German and Austrian laws, respectively, since November 6, 2023, we developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
For more information, please visit www.opgen.com
Forward-Looking Statements
This press release includes statements regarding a preferred stock financing transaction and the related transactions. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the risks and uncertainties relating to the consummation of final closing contemplated by the financing transaction for the Series E Preferred Shares, insolvency proceedings of Curetis GmbH and Ares Genetics GmbH, our use of proceeds from the sale of our securities, our ability to continue to finance our business and operations, the result of any alternatives to mitigate the Company’s cash position, including restructuring or refinancing of our debt, seeking additional debt or equity capital, reducing or delaying our business activities, selling assets, other strategic transactions or other measures, including obtaining relief under U.S. bankruptcy laws, and the terms, value and timing of any transaction resulting from such alternatives, our ability to satisfy debt obligations under our loan with the European Investment Bank should the final closing contemplated by the financing transaction for the Series E Preferred Shares not be consummated, and our liquidity and working capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business and condition, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen:
David E. Lazar
Chairman of the Board of Directors
InvestorRelations@opgen.com
FAQ
How much did David Lazar invest in OpGen through Series E Preferred Stock?
What will the proceeds from the investment be used for?
Who will take over as CEO of OpGen?
What was the outcome of OpGen's strategic process according to Oliver Schacht?
How many shares of Series E Preferred Stock did David Lazar acquire initially?
Who were the new board members appointed to OpGen?
What did the settlement agreements with EIB and Curetis entail?
What did David Lazar state regarding his investment in OpGen?
What role will Oliver Schacht play in OpGen following the transactions?
How many shares of common stock is each Series E Preferred Stock convertible into?
